International Stem Cell Corporation Arranges $3 Million Equity Financing
OCEANSIDE, Calif.–(BUSINESS WIRE)–International Stem Cell Corporation (OTCBB: ISCO - News) has entered into a subscription agreement with an accredited investor to sell three million dollars ($3,000,000) of Series C Preferred Stock at a price of $1.00 per share. The funding is to occur in three tranches. The first, for $700,000, closed August 20, 2008. The second closing for $1,300,000 is scheduled for September 23, 2008 and the final closing of $1,000,000 is scheduled for December 15, 2008, subject to determination by the investor that no material adverse event has occurred. The investor will ...
Source: International Stem Cell Corporation - September 13, 2008 Category: Stem Cells Authors: internationalstemcell Tags: biotechnology science health medicine Source Type: podcasts
International Stem Cell Corporation Arranges $3 Million Equity Financing
OCEANSIDE, Calif.–(BUSINESS WIRE)–International Stem Cell Corporation (OTCBB: ISCO - News) has entered into a subscription agreement with an accredited investor to sell three million dollars ($3,000,000) of Series C Preferred Stock at a price of $1.00 per share. The funding is to occur in three tranches. The first, for $700,000, closed August 20, 2008. The second closing for $1,300,000 is scheduled for September 23, 2008 and the final closing of $1,000,000 is scheduled for December 15, 2008, subject to determination by the investor that no material adverse event has occ...
Source: International Stem Cell Corporation - September 13, 2008 Category: Stem Cells Authors: internationalstemcell Tags: biotechnology science health medicine Source Type: podcasts
International Stem Cell Corporation Arranges $3 Million Equity Financing
OCEANSIDE, Calif.–(BUSINESS WIRE)–International Stem Cell Corporation (OTCBB: ISCO - News) has entered into a subscription agreement with an accredited investor to sell three million dollars ($3,000,000) of Series C Preferred Stock at a price of $1.00 per share. The funding is to occur in three tranches. The first, for $700,000, closed August 20, 2008. The second closing for $1,300,000 is scheduled for September 23, 2008 and the final closing of $1,000,000 is scheduled for December 15, 2008, subject to determination by the investor that no material adverse event has occurred. The investor will ...
Source: International Stem Cell Corporation - September 13, 2008 Category: Stem Cells Authors: internationalstemcell Tags: biotechnology science health medicine Source Type: podcasts
International Stem Cell Corporation Arranges $3 Million Equity Financing
OCEANSIDE, Calif.–(BUSINESS WIRE)–International Stem Cell Corporation (OTCBB: ISCO - News) has entered into a subscription agreement with an accredited investor to sell three million dollars ($3,000,000) of Series C Preferred Stock at a price of $1.00 per share. The funding is to occur in three tranches. The first, for $700,000, closed August 20, 2008. The second closing for $1,300,000 is scheduled for September 23, 2008 and the final closing of $1,000,000 is scheduled for December 15, 2008, subject to determination by the investor that no material adverse event has occ...
Source: International Stem Cell Corporation - September 13, 2008 Category: Stem Cells Authors: internationalstemcell Tags: biotechnology science health medicine Source Type: podcasts
Meet Ken Aldrich the co-founder of International Stem Cell Corporation
Welcome to this podcast. I am Ken Aldrich, Chairman and co-founder of International Stem Cell Corporation.
International Stem Cell Corporation recently announced that our scientific team, led by our Chief Scientist, Dr. Elena Revazova, has created a new class of human stem cell lines that do not involve the use of fertilized eggs and may enable hundreds of millions of people of different sex, ages and racial groups to benefit from cell based therapy with cells that will not be rejected by the patients own immune system after transplanting. The article was published in the on line edition of the well known peer-review publi...
Source: International Stem Cell Corporation - December 30, 2007 Category: Stem Cells Authors: internationalstemcell Tags: biotechnology science health medicine Source Type: podcasts
